ChronoScale Corporation Common Stock (NASDAQ:CHRN) Shares Gap Up - Here's Why

Key Points

• CHRN shares gapped higher, opening at $19.46 versus a prior close of $18.74, but later traded at $17.67 on volume of 40,726 shares.
• Analyst sentiment remains weak: the stock has a consensus “Reduce” rating, with an average price target of $6.00; ratings consist of one Hold and one Sell.
• The company reported a quarterly loss of $0.12 per share on $18.4 million in revenue, alongside a negative net margin of 135.66%; institutional investors own 6.42% of outstanding shares.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $18.74, but opened at $19.46. ChronoScale Corporation Common Stock shares last traded at $17.67, with a volume of 40,726 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a report on Monday, August 24th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, ChronoScale Corporation Common Stock presently has a consensus rating of "Reduce" and an average price target of $6.00.

ChronoScale Corporation Common Stock Price Performance

The company has a current ratio of 0.51, a quick ratio of 0.51 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $21.91 and a two-hundred day moving average price of $16.19. The firm has a market capitalization of $2.64 billion, a price-to-earnings ratio of -3.36 and a beta of 1.00.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $18.40 million for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. As a group, research analysts forecast that ChronoScale Corporation Common Stock will post -0.1 EPS for the current year.

Institutional Trading of ChronoScale Corporation Common Stock

Large investors have recently modified their holdings of the company. J.Safra Asset Management Corp acquired a new position in ChronoScale Corporation Common Stock during the 2nd quarter valued at about $105,000. Osbon Capital Management LLC bought a new stake in shares of ChronoScale Corporation Common Stock during the second quarter valued at approximately $81,000. Roble Belko & Company Inc boosted its position in shares of ChronoScale Corporation Common Stock by 104.5% during the first quarter. Roble Belko & Company Inc now owns 2,338 shares of the company's stock worth $25,000 after buying an additional 1,195 shares during the period. Philadelphia Investment Partners LLC bought a new position in ChronoScale Corporation Common Stock in the 2nd quarter worth approximately $589,000. Finally, Harvey Capital Management Inc. acquired a new stake in ChronoScale Corporation Common Stock in the 2nd quarter valued at approximately $3,093,000. Institutional investors and hedge funds own 6.42% of the company's stock.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc NASDAQ: EKSO is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source